Opioids News and Research

RSS

An opioid is a chemical that works by binding to opioid receptors, which are found principally in the central nervous system and the gastrointestinal tract. The receptors in these two organ systems mediate both the beneficial effects and the side effects of opioids.

Inadequate treatment strategies make cancer patients suffer unnecessarily: Survey

Further results from the European Survey of Breakthrough Cancer Pain were presented for the first time today at the 6th Research Congress of the European Association for Palliative Care in Glasgow.

11 Jun 2010

CTT's Calmare Pain Therapy Treatment shows promise against CIPN

Competitive Technologies, Inc. today announced the presentation of results from a study that shows the successful treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy using CTT's Calmare Pain Therapy Treatment. A three-hour discussion led by principal investigator, Thomas J. Smith, M.D., Endowed Chair of Palliative Care Research and Medical Director of the Thomas Palliative Care Unit Virginia Commonwealth University's Massey Cancer Center, at the American Society of Clinical Oncology Annual Meeting, cited results of the study.

11 Jun 2010

FDA grants Collegium Fast Track designation for COL-172 opioid formulation

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of COL-172 for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time.

10 Jun 2010

Masimo announces full market release of Rainbow Acoustic Monitoring to provide RRa

Masimo, the inventor of Pulse CO-Oximetry and Measure-Through Motion and Low Perfusion pulse oximetry, announced today the full market release of its latest medical technology breakthrough—Masimo Rainbow Acoustic Monitoring— providing continuous and noninvasive respiration rate that is accurate, easy-to-use, and enhances patient tolerance.

7 Jun 2010

Walter Reed Army Medical Center to treat pain patients with CTT's Calmare Pain Therapy Treatment

Competitive Technologies, Inc. announced today that the Walter Reed Army Medical Center in Washington, D.C., has joined the growing list of organizations that will treat pain patients with CTT's Calmare Pain Therapy Treatment, as authorized by the Surgeon General of the U.S. Army and Commanding General of the U.S. Army Medical Command.

5 Jun 2010

Competitive Technologies to raise over $5M to accelerate sales of Calmare Pain Therapy Treatment

Competitive Technologies, Inc. today announced that it has signed an agreement to raise over $5 million by selling 2 million shares of equity to Crisnic Fund, S.A. based on a 15% discount from the volume weighted average price on the date the SEC declares the registration effective, as detailed in the 8-K being filed today.

2 Jun 2010

Relevare Pharmaceuticals to present CNSB015 Phase IIa results at international neuropathic pain congress

Relevare Pharmaceuticals Ltd. will present its recent Phase IIa proof-of-concept clinical trial data and extension study results for CNSB015 (flupirtine), its lead repositioned compound, at the Third International Congress on Neuropathic Pain on May 27 –30 in Athens, Greece.

28 May 2010

YM BioSciences initiates enrollment in nimotuzumab trial in brain metastases from NSCLC

YM BioSciences Inc., today announced that the first US patient has been enrolled in its randomized, double-blind trial evaluating nimotuzumab in patients with brain metastases from NSCLC at the Florida Cancer Institute - New Hope. This trial initiation follows recent clearance from the US FDA announced on January 26, 2010 allowing the Company to enroll patients at US clinical sites for two of its international and ongoing randomized, double-blind Phase II trials of nimotuzumab.

27 May 2010

Physician experts review current practices for pain management in cirrhotic patients

In the May issue of Mayo Clinic Proceedings, physician experts review current practices for pain management in cirrhotic patients. The physician experts reviewed all current literature available on PubMed and MEDLINE with no limits in the search to recommend a uniform and practical guide to approaching analgesia in the cirrhotic patients.

27 May 2010

FDA grants priority review for Alkermes' VIVITROL sNDA for opioid dependence

Alkermes, Inc. today announced that the supplemental New Drug Application (sNDA) for VIVITROL® (naltrexone for extended-release injectable suspension) for opioid dependence has been designated a priority review by the U.S. Food and Drug Administration (FDA).

25 May 2010

Elite Pharmaceuticals acquires hydromorphone hydrochloride tablets from Mikah Pharma

Elite Pharmaceuticals, Inc. announced today the acquisition of a currently approved Abbreviated New Drug Application (ANDA) for hydromorphone hydrochloride 8 mg tablets from Mikah Pharma LLC. The hydromorphone hydrochloride tablets are the generic equivalent of Dilaudid® 8 mg.

25 May 2010

CTT's Calmare Pain Therapy Treatment decreases pain associated with CIPN

Competitive Technologies, Inc. today announced the issuance of an abstract from a study which has shown the successful treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy using CTT's Calmare Pain Therapy Treatment.

21 May 2010

Collegium Pharmaceutical receives Notice of Allowance from USPTO for DETERx technology

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that it has received Notice of Allowance from the U.S. Patent and Trademark Office for its patent application "Abuse-Deterrent Drug Formulations", US Patent Application Number 11/149,867. The Notice of Allowance is the USPTO's official communication that the Company's application has successfully completed examination and that a patent will be issued.

20 May 2010

Use of life-ending drugs without explicit patient request occurs in hospital, among elderly patients

Despite fears to the contrary, the use of drugs to end life without patient request has not increased since euthanasia was legalized in Belgium, states an article in CMAJ.

19 May 2010

Research findings help explain diverse genetic susceptibility for alcohol use disorders

A genetic variant of a receptor in the brain's reward circuitry plays an important role in determining whether the neurotransmitter dopamine is released in the brain following alcohol intake, according to a study led by researchers at the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health. Dopamine is involved in transmitting the euphoria and other positive subjective effects produced by alcohol.

19 May 2010

Warnings about a ruined appearance is best way to reduce tanning salon visits

What's the most effective way to convince young women to cut back on their indoor tanning, a habit that hikes their risk of melanoma, the deadliest form of skin cancer, by 75 percent? Warn them that it will cause leathery, wrinkled skin.

18 May 2010

FDA approves ROXRO PHARMA's SPRIX Nasal Spray

ROXRO PHARMA, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SPRIX™ (ketorolac tromethamine) Nasal Spray, for the short-term (up to 5 days) management of acute moderate to moderately severe pain that requires analgesia at the opioid level.

17 May 2010

Titan Pharmaceuticals reports total revenues of $2.4M for first-quarter 2010

Titan Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2010.

17 May 2010

Tranzyme Pharma to present data on prokinetic agent TZP-101 in GI recovery at ASCRS 2010

Tranzyme Pharma today announced that Philippa Charlton, MD, Tranzyme's Medical Director, and her colleagues G. Bochicchio, J.C. Pezullo, G. Kosutic, and A. Senagore, will present a poster entitled "The Prokinetic Agent TZP-101 (a Ghrelin Agonist) Accelerates GI Recovery in Partial Colectomy Patients Independently of Total Opioid Use and Type of Surgery" at the upcoming 2010 Annual Scientific Meeting of the American Society of Colon and Rectal Surgeons (ASCRS; Minneapolis, May 15-19).

17 May 2010

Pain rehabilitation programs can help patients break the cycle of worsening pain: Mayo Clinic Health Letter

Chronic pain -- whether from headaches, back pain or conditions such as fibromyalgia -- can interfere with work, day-to-day activities and relationships. All too often, pain relief treatments are ineffective and can lead to a downward spiral of frustration, decreased functioning, stress, isolation -- and worsening pain.

13 May 2010

Opioids News and Research

Further Reading

Inadequate treatment strategies make cancer patients suffer unnecessarily: Survey

CTT's Calmare Pain Therapy Treatment shows promise against CIPN

FDA grants Collegium Fast Track designation for COL-172 opioid formulation

Masimo announces full market release of Rainbow Acoustic Monitoring to provide RRa

Walter Reed Army Medical Center to treat pain patients with CTT's Calmare Pain Therapy Treatment

Competitive Technologies to raise over $5M to accelerate sales of Calmare Pain Therapy Treatment

Relevare Pharmaceuticals to present CNSB015 Phase IIa results at international neuropathic pain congress

YM BioSciences initiates enrollment in nimotuzumab trial in brain metastases from NSCLC

Physician experts review current practices for pain management in cirrhotic patients

FDA grants priority review for Alkermes' VIVITROL sNDA for opioid dependence

Elite Pharmaceuticals acquires hydromorphone hydrochloride tablets from Mikah Pharma

CTT's Calmare Pain Therapy Treatment decreases pain associated with CIPN

Collegium Pharmaceutical receives Notice of Allowance from USPTO for DETERx technology

Use of life-ending drugs without explicit patient request occurs in hospital, among elderly patients

Research findings help explain diverse genetic susceptibility for alcohol use disorders

Warnings about a ruined appearance is best way to reduce tanning salon visits

FDA approves ROXRO PHARMA's SPRIX Nasal Spray

Titan Pharmaceuticals reports total revenues of $2.4M for first-quarter 2010

Tranzyme Pharma to present data on prokinetic agent TZP-101 in GI recovery at ASCRS 2010

Pain rehabilitation programs can help patients break the cycle of worsening pain: Mayo Clinic Health Letter

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News